Neoplasms, Breast
71
1
2
49
Key Insights
Highlights
Success Rate
77% trial completion
Published Results
35 trials with published results (49%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
21.1%
15 terminated out of 71 trials
76.6%
-9.9% vs benchmark
15%
11 trials in Phase 3/4
71%
35 of 49 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 49 completed trials
Clinical Trials (71)
Study of ESG401 in Adults With Solid Tumors
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer
Early Rehabilitation for Breast Cancer - A Randomized Control Trial
ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA
GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer
Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Pre- Versus Postoperative Accelerated Partial Breast Irradiation
Lapatinib and Bevacizumab for Metastatic Breast Cancer
Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study
Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.
Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer